Point Biopharma describes PSMA radioligand 225Ac-PNT2001 for cancer therapy

Oct. 21, 2022

At the recent EANM meeting, Point Biopharma Global Inc. presented preclinical details on the development of 177Lu-PNT2001 and 225Ac-PNT2001 for the treatment of prostate cancer.

BioWorld Science Conferences Cancer

Today's news in brief

BioWorld

BioWorld briefs for Sept. 22, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Sept. 22, 2025.

The ‘molecular revolution’ driving R&D of new cancer therapeutics

BioWorld Asia

“New explosions in biotechnology are allowing us to interrogate cancers at a very sophisticated level compared to before,” Dennis Slamon told audience members at...

Elderly woman holding illustration of brain with missing puzzle piece

Remynd’s REM-127 yields positive phase II data in Alzheimer’s

BioWorld

Remynd NV has turned in positive phase IIa data for a new target in Alzheimer’s disease, showing that restoring calcium homeostasis in neurons reduces levels of...

The domino effect of cutting mRNA vaccine research

BioWorld

In August, a press release from HHS announced the cancellation of 22 vaccine research projects based on mRNA, the latest available technology aimed at developing...